Warning: fopen(/home/virtual/enm-kes/journal/upload/ip_log/ip_log_2026-03.txt): failed to open stream: Permission denied in /home/virtual/lib/view_data.php on line 100 Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 101 Metformin and Adipose Tissue: A Multifaceted Regulator in Metabolism, Inflammation, and Regeneration
Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search
Advanced Search
mobile menu button

Articles

Page Path
HOME > Endocrinol Metab > Volume 40(4); 2025 > Article
Review Article
Diabetes, obesity and metabolism Metformin and Adipose Tissue: A Multifaceted Regulator in Metabolism, Inflammation, and Regeneration
Keypoint
- This review discusses metformin’s actions on white and brown adipose tissues, extracellular matrix remodeling, mature adipocytes, and adipose-derived stem cells.
- Acting through both AMPK-dependent and independent pathways, metformin influences adipogenesis, lipolysis, adipokine secretion, fibrosis, and senescence.
- Drug concentration impacts the biological effects of metformin, underscoring the need for physiologically relevant experimental models.
- These insights contribute to a deeper understanding of metformin’s therapeutic potential in metabolic and age-related disorders.
Xin-Li Wei1,2orcid, Ming-Hao Tao3orcid, Run-Hao Li4orcid, Shi-Hui Ge5orcid, Wei Xiao2orcid
Endocrinology and Metabolism 2025;40(4):523-538.
DOI: https://doi.org/10.3803/EnM.2025.2371
Published online: August 8, 2025

1The First Clinical Medical School, Henan University of Chinese Medicine, Zhengzhou, China

2State Key Laboratory of Technologies for Chinese Medicine Pharmaceutical Process Control and Intelligent Manufacture, Lianyungang, China

3Department of Endocrinology and Metabolism, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China

4Department of Human Anatomy & Histoembryology, School of Basic Medical Sciences, Fudan University, Shanghai, China

5Department of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, China

Corresponding author: Wei Xiao. State Key Laboratory of Technologies for Chinese Medicine Pharmaceutical Process Control and Intelligent Manufacture, Jiangning Industrial City, Economic and Technological Development Zone, Lianyungang, Jiangsu 222001, China Tel: +86-518-81152310, Fax: +86-518-81152310, E-mail: xw_kanion@163.com
• Received: March 13, 2025   • Revised: May 9, 2025   • Accepted: June 5, 2025

Copyright © 2025 Korean Endocrine Society

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 4,924 Views
  • 151 Download
  • 5 Web of Science
  • 6 Crossref
  • 5 Scopus
prev next
Full Article

Download PDF Download PDF

  • Metformin, a first-line treatment for type 2 diabetes mellitus (T2DM), has garnered attention due to its pleiotropic effects beyond glycemic control. In addition to improving insulin sensitivity and inhibiting hepatic gluconeogenesis, metformin modulates inflammation, oxidative stress, and cellular metabolism, particularly within adipose tissue. Adipose tissue is a crucial endocrine organ that plays a central role in metabolic homeostasis and is integral to obesity and T2DM pathogenesis. This review discusses the actions of metformin on white and brown adipose tissues, extracellular matrix remodeling, mature adipocytes, and adipose-derived stem cells. Through both AMP-activated protein kinase-dependent and independent pathways, metformin influences adipogenesis, lipolysis, adipokine secretion, fibrosis, and cellular senescence. We also focus on how the drug concentration influences its biological effects, emphasizing the necessity of physiologically relevant experimental models. These insights deepen our understanding of metformin’s therapeutic potential in metabolic and age-related disorders.
  • Keywords: Metformin; Adipose tissue; Pharmacology
Metformin has been widely utilized in clinical practice for decades as a first-line therapy for type 2 diabetes mellitus (T2DM). It effectively controls blood glucose levels by increasing insulin sensitivity, inhibiting hepatic glucose production, and promoting glucose uptake in peripheral tissues. Recent research indicates that metformin may possess additional therapeutic properties beyond traditional antidiabetic effects, such as anti-cancer [1], anti-inflammatory, and antioxidant properties [2], and these possibilities have attracted extensive scientific interest.
Adipose tissue, historically viewed merely as a passive energy storage organ, is now recognized as an active endocrine organ critical for maintaining systemic metabolic homeostasis [3]. Metformin exerts multifaceted effects on adipose tissue by modulating adipocyte differentiation, lipid metabolism, and adipokine secretion; this provides a mechanistic link between adipose tissue remodeling and the broad metabolic benefits of metformin.
Although metformin has been extensively studied, a comprehensive review encompassing its developmental history, clinical applications, molecular mechanisms, newly discovered therapeutic functions, and specific mechanisms in adipose tissue remains lacking. Thus, this review aims to provide a systematic overview of metformin, particularly emphasizing its recently discovered therapeutic potential and its effects on adipose tissue. It seeks to establish mechanistic connections between adipocyte pathophysiology and systemic metabolic outcomes, thereby informing translational research strategies for therapeutic optimization.
Brief developmental history
Metformin, a classic hypoglycemic drug used for nearly a century, traces its origins back to botanical therapies in medieval Europe [4]. Although diabetes pathophysiology was poorly understood historically, plants rich in guanidine compounds, such as Galega officinalis (goat’s rue), were utilized as herbal remedies for polyuria symptoms [5]. Early 20th-century scientific advances revealed guanidine derivatives as active hypoglycemic constituents in G. officinalis [6]. Subsequently, various guanidine derivatives—including monoguanidine, diguanidine, and phenformin—were artificially synthesized or isolated [7]. Initially, metformin and related guanidine compounds were withdrawn from clinical use due to concerns about biological toxicity and heightened risks of lactic acidosis. Additionally, the introduction of insulin as a direct hypoglycemic treatment relegated metformin to obscurity for half a century [8,9]. Scientific and clinical interest in metformin gradually re-expanded due to its safe hypoglycemic properties and potential applications in other diseases like influenza and malaria [8,9]. Through sustained efforts from visionary clinicians such as Jean Sterne, clinical trials conclusively addressed previous safety concerns regarding metformin [10-12]. On December 29, 1994, the U.S. Food and Drug Administration officially approved metformin for sale in the United States [7]. Today, metformin is globally acknowledged as a first-line diabetes treatment, used by nearly 70% of diabetes patients worldwide, either alone or in combination with other antidiabetic agents [13]. With a large patient population and increasing clinical studies, a broader spectrum of metformin’s effects has gradually emerged.
Clinical use
As a first-line treatment for T2DM, metformin has unequivocally demonstrated efficacy in lowering blood glucose. It can be administered as monotherapy or combined with other hypoglycemic drugs. When used alone, metformin exhibits superior glucose control compared to other oral hypoglycemic agents [14]. Monotherapy can lower glycosylated hemoglobin A1C (HbA1c) levels by approximately 1% to 1.5% (14 mmol/mol) [15,16]. Furthermore, metformin more efficaciously controls blood glucose and body weight than dipeptidyl peptidase 4 inhibitors [17]. Recent clinical studies suggest that combining metformin with glycine and liraglutide can improve HbA1c control [18]. Metformin is particularly effective in preventing diabetes progression among prediabetic populations, notably patients with histories of gestational diabetes, severe obesity, or elevated fasting blood glucose [19,20]. Despite the emergence of newer antidiabetic agents such as glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 inhibitors, metformin remains the recommended first-line therapy due to its affordability, consistent efficacy, and favorable safety profile. Additionally, metformin has shown potential therapeutic benefits for chronic kidney disease, cardiovascular disease prognosis, polycystic ovary syndrome (PCOS), cognitive decline and Alzheimer’s disease, and even osteoarthritis [19,21-24].
Compared to other glucose-lowering medications, metformin poses a lower risk of hypoglycemia and lactic acidosis. Gastrointestinal intolerance is its primary side effect, and gradual dose titration effectively mitigates this issue [25]. The minimum recommended dose is 500 mg daily, with an optimal effective dose of 2,000 mg daily. For adults, the maximum dose of regular tablets is 2,550 mg daily, while the recommended maximum dose for extended-release formulations, which better reduce gastrointestinal adverse effects, is 2,000 mg daily [26]. Recent clinical guidelines from the American Diabetes Association have revised precautions regarding metformin use, affirming that it is safe to use in patients with an estimated glomerular filtration rate ≥30 mL/min/1.73 m2 [25]. Notably, metformin may contribute to vitamin B12 deficiency; hence, periodic vitamin B12 screening is advisable [27].
Pharmacokinetics of metformin
The physicochemical properties of metformin (1,1-dimethylbiguanide hydrochloride) originate from its molecular structure, which exists predominantly as an organic cation under physiological pH. Initially, metformin absorption primarily takes place in the jejunum, where it enters intestinal epithelial cells through the luminal side via the plasma membrane monoamine transporter (PMAT, encoded by the solute carrier family 29 member 4 [SLC29A4] gene) [28]. Recent studies have shown that this transporter protein is closely associated with gastrointestinal adverse reactions [29]. Subsequently, metformin reaches the systemic circulation by crossing the basolateral membrane of intestinal epithelial cells through organic cation transporter 1 (OCT1, encoded by the SLC22A1 gene) [28]. However, the types of membrane protein transporters involved vary among different organs and cell types. For instance, OCT1 is expressed not only in intestinal epithelial cells but also on hepatocyte cell membranes, alongside OCT3 (encoded by the SLC22A3 gene) [30,31]. Moreover, OCT1 is expressed on adipocytes, and its expression is notably elevated in obese individuals [32]. OCT2 (encoded by the SLC22A2 gene) is predominantly present in renal epithelial cells, sharing a similar cation recognition mechanism with OCT1 [33]. Additionally, human multidrug and toxin extrusion proteins 1 and 2 (MATE1 and MATE2, encoded by the SLC47A1 and SLC47A2 genes, respectively) have been identified on the apical membrane of proximal renal tubule cells, playing a critical role in metformin excretion [34-36]. Notably, OCTs and MATEs have also been identified in endometrial epithelial cells, implicating them in PCOS treatment [37]. At the intracellular organelle level, metformin regulates lipid metabolism through mitochondrial oxidized nicotinamide adenine dinucleotide (NAD+) transporters, particularly SLC25A47 [38,39]. Therefore, the distribution and function of metformin transport proteins expressed in the plasma and organelle membranes across various tissues significantly influence metformin’s therapeutic efficacy.
Debates regarding experimental concentrations of metformin
Researchers have drawn attention to the concentrations of metformin utilized in experimental research as a concern [40]. Numerous previous in vitro studies employed relatively high metformin concentrations, often inconsistent with the actual plasma concentrations observed in vivo [41-43]. This discrepancy has raised questions about the relevance of proposed mechanisms. For example, metformin only inhibits mitochondrial respiratory chain complex I at supratherapeutic concentrations [44]. Clinical evidence supports this concern, as the recommended metformin dose is approximately 2 g/day. Given its short half-life and limited oral bioavailability (around 50%), plasma concentrations rarely surpass 40 μM [41,45]. Animal studies indicate that therapeutic metformin concentrations range from approximately 40 to 70 μM in the portal vein and from 10 to 40 μM in the systemic circulation [42]. Researchers are increasingly using lower, physiologically relevant metformin concentrations to better understand its mechanisms within realistic in vivo contexts [46,47]. However, replicating prolonged therapeutic blood concentrations remains challenging in tissue and cell culture systems. Therefore, although comparable transient concentrations may be attainable, further research is needed to elucidate the mechanisms underpinning metformin’s sustained effects. Tissue distribution studies employing isotopic labeling, such as with 11C-labeled metformin, have shown predominant accumulation in the kidneys and liver, with hepatic uptake unaffected by pathological changes seen in non-alcoholic fatty liver disease [48]. Metformin also accumulates in the salivary glands, skeletal muscle, and intestinal tissues. These insights significantly enhance our understanding of the tissue-specific effects and potential therapeutic targets of metformin [49,50].
Molecular mechanisms
Recent research into the subcellular mechanisms of metformin primarily focuses on mitochondria and lysosomes. Although the exact concentration at which metformin exerts its effects remains debated, the classical view suggests that it inhibits respiratory chain complex I on the mitochondrial membrane [44]. Complex I catalyzes the dehydrogenation of reduced nicotinamide adenine dinucleotide (NADH) to NAD+, subsequently facilitating the generation of adenosine triphosphate (ATP) through the Krebs cycle. Inhibition of complex I reduces the intracellular ratio of ATP to adenosine monophosphate (AMP) [51]. Changes in the ratios of ATP, adenosine diphosphate (ADP), and AMP affect the phosphorylation of threonine 172 on the α subunit of AMP-activated protein kinase (AMPK) and thus affect AMPK activity [52]. In hepatic cells, activation of AMPK partly involves the protein-threonine kinase liver kinase B1 (LKB1), a critical component of metformin’s molecular mechanism [53]. This pathway significantly contributes to conditions such as metastatic prostate cancer, cardiovascular disease, and non-small cell lung cancer, a fact that provides insights into the anti-cancer effects of metformin [54-56]. In 2017, another mechanism was identified, where the glycolytic intermediate fructose-1,6-bisphosphate (FBP) regulates AMPK activity through aldolase enzymes, independently of ATP, ADP, and AMP concentrations [57]. Furthermore, it was discovered that aldometanib, an aldolase inhibitor, activates AMPK through the lysosomal pathway, and notably prolongs the healthy lifespan of nematodes and mice [58]. AMP accumulation can also inhibit the conversion of ATP to cyclic AMP (cAMP), subsequently decreasing protein kinase A (PKA) activity [59]. The role of this pathway in metformin-induced suppression of triple-negative breast cancer stem cells has also been validated [60]. An analysis of metformin’s mechanisms using phosphoprotein enrichment and quantitative proteomics indicated that 44% of proteins function via an LKB1-dependent mechanism [61]. These findings suggest that alternative pathways, such as aldolases and cAMP-related signaling, remain promising areas for further investigation. Additionally, a regulatory effect on the cellular redox state via non-competitive inhibition of mitochondrial glycerophosphate dehydrogenase, leading to reduced blood glucose levels, has been confirmed [62]. Importantly, this gluconeogenesis-inhibiting mechanism occurs at low metformin concentrations [63].
Traditionally, lysosomes have been recognized primarily as cellular degradation centers. However, deeper insights now acknowledge their involvement in regulating cellular metabolism and signal transduction [64]. A pivotal study in 2016 demonstrated that metformin promotes the translocation of scaffold protein AXIN, recruiting LKB1 to the lysosomal surface by directly interacting with vacuolar-type H(+)-ATPase (V-ATPase) regulators [65]. This interaction subsequently activates AMPK while concurrently inhibiting mechanistic target of rapamycin complex 1 (mTORC1) [65]. v-ATPase is a eukaryotic protein complex responsible for proton transport from the cytoplasm to lysosomes against concentration gradients [66]. Subsequent research further confirmed that at low concentrations, metformin inhibits v-ATPase activity by facilitating the binding of presenilin enhancer 2 (PEN2) with ATPase H+ transporting accessory protein 1 (ATP6AP1), an auxiliary v-ATPase factor, thereby activating AMPK independently of AMP or ADP accumulation [47].
Research on the subcellular mechanisms of metformin has predominantly emphasized mitochondria and lysosomes, and these pathways frequently converge on the key signaling node, AMPK. Indeed, AMPK plays a central role in mediating metformin’s effects, regulating cellular glucose metabolism, lipid metabolism, amino acid metabolism, autophagy, and mitochondrial function [67]. A promising focus in ongoing research may be the mechanisms by which metformin acts upon lysosomes at physiologically relevant concentrations. Further exploration of these pathways may uncover additional therapeutic potential of metformin in treating conditions such as diabetes, cancer, and aging.
The primary function of adipose tissue is lipid storage and metabolism. Fatty acids stored within adipose tissue predominantly originate from triacylglycerols (TAGs), either transported by plasma lipoproteins or synthesized de novo within adipocytes. Lipoprotein lipase (LPL), secreted by adipocytes or muscle cells, binds to glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPIHBP1) located on the endothelial surface of capillaries, facilitating the hydrolysis of circulating lipoproteins. LPL enzymatically cleaves triglycerides within chylomicrons and very-low-density lipoproteins (VLDLs), releasing free fatty acids that are subsequently absorbed by adipocytes through CD36-positive fatty acid translocase on the plasma membrane [68]. Glucose uptake into adipocytes primarily occurs via insulin-responsive glucose transporter 4 (GLUT4) localized on the cell membrane. Under low plasma insulin conditions, GLUT4 remains within intracellular vesicles. Upon insulin stimulation, GLUT4 relocates to the plasma membrane, where it facilitates glucose entry into cells [69].
Within adipocytes, glucose serves as a primary energy source and supplies 3-phosphoglycerol for TAG synthesis through glycolysis and the tricarboxylic acid cycle, while also providing acetyl coenzyme A for de novo lipogenesis [70]. The conversion of 3-phosphoglycerol and fatty acids—from glycolysis, endogenous adipocyte stores, or exogenous sources—is catalyzed by enzymes such as glycerol-3-phosphate acyltransferase (GPAT) and 1-acylglycerol-3-phosphate O-acyltransferase (AGPAT), forming diacylglycerol (DAG). DAG is subsequently esterified by diacylglycerol acyltransferase (DGAT) into TAG. Under conditions of elevated energy demand, such as fasting, exercise, or stress, hormones including glucagon, catecholamines, natriuretic peptides, thyroid hormones, and tumor necrosis factor-α (TNF-α) stimulate lipolysis by increasing intracellular cAMP and cyclic guanosine monophosphate (GMP). This mobilization of stored fat begins with adipose triacylglyceride lipase (ATGL, encoded by patatin like domain 2, triacylglycerol lipase [PNPLA2]), which hydrolyzes TAG into DAG and a free fatty acid. Hormone-sensitive lipase (HSL, encoded by lipase E, hormone sensitive type [LIPE]) further hydrolyzes DAG to monoacylglycerol (MAG) and another fatty acid [71]. Lastly, monoacylglycerol lipase (MAGL) hydrolyzes MAG into glycerol and an additional fatty acid [71].
In recent decades, adipose tissue has increasingly been recognized as playing important endocrine roles, in addition to its function in energy storage and thermal insulation. Advances in basic science and analytical techniques have shown that adipose tissue comprises diverse cell types, including immune cells, stromal stem cells, and others [72]. Since the discovery of leptin in the 1990s, our understanding of adipose tissue has expanded beyond its role in energy storage and expenditure to include its endocrine functions.
The impact of metformin on various categories of adipose tissue
From functional and morphological standpoints, adipose tissue is classified into white adipose tissue (WAT) and brown adipose tissue (BAT), each primarily composed of its respective adipocyte subtype.The distribution and characteristics of different types of adipose tissue and the effects of metformin on them are illustrated in Fig. 1.
Brown adipose tissue
BAT is typically located in highly vascularized areas in both humans and mice [73]. Neonates exhibit BAT analogous to that found in mice, notably in the scapular region [74], although this BAT diminishes with age. Positron emission tomography imaging has revealed residual BAT in adults, particularly around the neck, clavicle, and vertebral regions [75]. BAT, which is predominantly composed of brown adipocytes, shares immunological markers similar to skeletal muscle and uniquely expresses myogenic factor 5 (Myf5) and paired box 7 (Pax7), which are absent in white adipocytes. This indicates that brown adipocytes derive from a distinct lineage [76]. The transcriptional regulator PR domain-containing 16 (PRDM16) activates peroxisome proliferator-activated receptor gamma (PPAR-γ) expression, facilitating differentiation into brown adipocytes and skeletal muscle cells, but not white adipocytes [77]. PRDM16 is pivotal in thermogenesis and broader metabolic regulation [78]. Morphologically, brown adipocytes feature multiple small lipid droplets dispersed throughout their cytoplasm and abundant mitochondria, essential for their thermogenic function. Uncoupling protein 1 (UCP1), a key thermogenesis mediator, disrupts oxidative phosphorylation upon activation, inhibiting ATP production and dissipating energy as heat via non-shivering thermogenesis [77].
Given BAT’s unique energy-expenditure role, metformin may exert therapeutic benefits by upregulating its thermogenic function. Unlike energy-storing adipose tissue, BAT predominantly functions in energy consumption and heat production, and metformin promotes BAT proliferation, differentiation, and metabolic capacity [79]. Metformin enhances BAT activity by upregulating BAT-specific genes such as UCP1 via the nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) signaling pathway [80]. Additionally, metformin administration in obese mouse models increases BAT-specific markers, including UCP1, ELOVL fatty acid elongase 3 (Elovl3), and Cidea [81]. Its thermogenic capacity can also be maintained through activation of the deacetylase sirtuin 1 (SIRT1), reducing brown adipocyte senescence. Studies in progeroid mice have demonstrated that metformin-induced SIRT1 activation significantly reduces mitochondrial oxidative stress in brown adipocytes, alleviates pericellular inflammation, and delays senescence-related functional decline [82]. Furthermore, metformin increases BAT activity and the clearance of VLDL absorbed by BAT, intensifying excess energy consumption [83]. Metformin also attenuates the inflammatory response in BAT induced by hypoxia-inducible factor-α (HIF-α), restoring insulin sensitivity in brown adipocytes [84]. Long-term metformin use reduces inflammation in BAT, increases systemic energy expenditure, and promotes BAT activation. Investigation into metformin’s positive impact on BAT differentiation and metabolism highlights its therapeutic potential, making BAT a promising intervention target [85].
However, some studies suggest that metformin may not significantly increase BAT activity; notably, these studies were short-term (less than 2 weeks) in mouse models [85]. However, it is worth noting that, except for the study on VLDL uptake conducted in animal models, the aforementioned findings were largely derived from experimental models using metformin at millimolar concentrations. It remains unclear whether these supraphysiological levels can be replicated in vivo or may lead to unforeseen side effects. Moreover, given the limited distribution of BAT in the human body, whether its functional changes are sufficient to induce significant metabolic improvements remains a matter of debate.
White adipose tissue
WAT is the predominant adipose depot in the human body, widely distributed across visceral and subcutaneous regions, along with distinct localized fat reservoirs. It primarily consists of white adipocytes, characterized by a single large lipid droplet and relatively fewer mitochondria [3]. The principal functional role of white adipocytes is lipid storage within intracellular droplets during periods of energy surplus and mobilization of these energy reserves via metabolic cascades in response to physiological demands [86]. This pivotal function contributes significantly to overall energy homeostasis. Additionally, WAT provides essential thermal insulation, aiding in maintaining stable body temperature.
After 14 weeks of metformin treatment in mice, fibroblast growth factor 21 expression in WAT significantly increased, suppressing white adipocyte differentiation [81]. Concurrently, metformin reduced interleukin-17 (IL-17) levels, thereby alleviating the inflammatory state in mice [81]. Together, these effects contributed to enhanced glucose metabolism and reduced metabolic disturbances. Metformin also lowers the levels of various pro-inflammatory cytokines through decreased macrophage infiltration and inhibition of macrophage polarization, thus improving insulin sensitivity in adipose tissue [87]. Metabolomic and transcriptomic analyses indicate that short-term metformin administration downregulates adipose tissue genes involved in fatty acid synthesis, altering circulating fatty acid flux. Additionally, metformin suppresses genes related to AMPK inhibition, enhancing adipose insulin sensitivity [88]. Beyond metabolic effects, clinical research has demonstrated that metformin-induced weight loss, improved insulin sensitivity, and reduced pro-inflammatory cytokines in patients with metabolic syndrome correlate with increased adiponectin and decreased leptin and resistin secretion [89]. Notably, metformin’s effects on increasing adiponectin and reducing leptin secretion are especially pronounced in obese individuals with a body mass index exceeding 30 kg/m2 [90]. These adipokines play crucial roles in appetite regulation, insulin sensitivity, and systemic inflammation. Thus, metformin’s direct impact on adipose tissue modulates systemic metabolic homeostasis by regulating adipokine secretion.
Metformin exerts multifaceted actions on WAT, encompassing anti-inflammatory effects, metabolic improvements, and promoting adipose browning. These benefits primarily result from AMPK pathway activation, modulation of macrophage polarization, and regulation of adipokine balance. Together, these mechanisms underpin metformin’s anti-obesity and antidiabetic properties mediated through adipose tissue [91]. However, the precise molecular targets responsible for these effects remain unclear. Moreover, numerous studies have reported that metformin inhibits adipocyte differentiation and downregulates fatty acid synthesis—findings that seemingly contradict the assumption that glucose-lowering effects involve increased energy substrate uptake in adipose tissue [81,88]. The mechanisms underlying these paradoxical observations require further investigation.
Anatomical distribution of adipose tissue
In addition to morphological distinctions, adipose tissue’s anatomical distribution has significant clinical implications. Adipose tissue is typically categorized into visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT). VAT accounts for approximately 10% to 20% of total body fat mass, primarily surrounding the mesentery and digestive organs. Conversely, SAT constitutes over 80% of body fat, predominantly located in the gluteal, femoral, and abdominal regions. Adult men generally possess higher VAT proportions than women. Clinically, VAT has a stronger association with hepatic steatosis, insulin resistance, and cardiovascular diseases than SAT, likely due to its ability to deliver substantial lipid amounts directly to the liver through the portal vein, causing metabolic disturbances in hepatocytes [71,92]. Owing to limited stem cell recruitment and reduced adipogenic capacity in VAT, adipocytes in this depot tend to hypertrophy. In contrast, SAT adipocytes tend toward proliferation due to an abundance of mesenchymal progenitor cells and elevated adipogenic activity [3,93]. In contrast, dyslipidemia has been associated with VAT, whereas blood glucose and insulin abnormalities have been linked to SAT [94].
Drug therapies typically target SAT, aligning well with metformin’s therapeutic profile [46]. In clinical studies, metformin-induced weight loss correlated significantly with SAT reduction, whereas its effects on visceral or hepatic fat were comparatively modest [95]. Metformin may exert beneficial effects by improving energy metabolism and insulin sensitivity in SAT through mechanisms such as reducing adipocyte hypertrophy and alleviating inflammatory responses [89,96]. Within VAT, metformin increases metabolic function primarily by reducing pro-inflammatory cytokines (e.g., TNF-α and IL-6) and oxidative stress, consequently improving systemic inflammation and insulin resistance [97].
Metformin exhibits a “dual effect” on SAT and VAT. In SAT, metformin predominantly reduces tissue volume and enhances metabolic function, whereas in VAT, its actions mainly involve modulation of inflammation and fibrosis rather than pronounced volume reduction. These divergent effects may stem from inherent biological differences between these adipose depots and their distinct roles in systemic metabolism.
Adipose tissue is a multifunctional organ predominantly composed of adipocytes, but it also includes diverse cell types, such as adipocyte precursor cells, adipose-derived stem cells (ASCs), and immune cells. These components constitute the stromal vascular fraction. Disruptions or alterations in these cellular constituents or in the extracellular matrix (ECM) can impair adipose tissue functionality and contribute to disease progression. Pathological conditions modulate the adaptive and maladaptive responses of adipose tissue, thus influencing systemic metabolic homeostasis. Effects of metformin on them are illustrated in Fig. 2.
Extracellular matrix
The ECM, which is primarily composed of collagen, fibrin, and proteoglycans, constitutes an essential microenvironment for various cell types [98]. Current evidence highlights a strong association between collagen VI expression, adipocyte expansion, and systemic metabolic regulation. Under hypoxic conditions, increased expression of collagen I and III occurs, largely due to HIF-1α activation [99]. It is reasonable to postulate that the ECM likely influences adipose tissue metabolism through pathological hypoxia and inflammatory responses, driving upregulation of various ECM components. This hinders orderly adipocyte expansion and disrupts adipocyte metabolic function. Local tissue dysfunction—characterized by adipocyte death, impaired angiogenesis, and chronic inflammation—directly diminishes insulin sensitivity and metabolic performance of adipocytes, thereby contributing to systemic metabolic dysregulation [100]. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases exert a pivotal role in stimulating ECM synthesis [100].
Metformin has demonstrated the capability to inhibit transforming growth factor-beta1 (TGF-β1)-induced fibrosis via AMPK activation, thus mitigating adipocyte senescence and insulin resistance arising from ECM abnormalities [101]. MMPs are also therapeutic targets of metformin, with significantly reduced expression levels of major fibrogenic MMPs following treatment [102]. Regarding fibrosis origins, metformin limits mesenchymal stem cell (MSC) differentiation into myofibroblasts through AMPK activation and inhibition of the phosphoinositide 3-kinase (PI3K) pathway, restoring redox homeostasis [102]. Similar effects were observed in mouse SAT [103]. Therapeutically, inhibition of the downstream PI3K/Akt signaling pathway reduces adipogenesis and improves ECM microenvironments, potentially ameliorating T2DM [104]. Whereas autophagy exerts beneficial cellular functions, deficiencies in autophagy genes alter ECM remodeling induced by obesity [105]. High metformin concentrations can reduce type I collagen deposition and inflammatory cytokine expression in adipose tissue, promoting improved wound healing after burn injuries [106]. However, whether the high concentrations (100 mM) used in in vitro experiments correlate to comparable effects in vivo remains an open question that warrants further investigation. In addition to adipose tissue, it is noteworthy that the regulatory effect of metformin on ECM has been harnessed in targeted nanomedicine to enhance the efficacy of targeted therapy, thereby substantiating its regulatory impact on ECM generation [107].
Metformin regulates multiple cellular targets and signaling pathways within the ECM, exerting effects both indirectly through modulation of cell differentiation and directly by structurally improving the ECM microenvironment. These mechanisms contribute to restoring ECM metabolic homeostasis, positioning metformin as a promising therapeutic agent for obesity- and diabetes-associated adipose fibrosis.
Mature adipocytes
Mature adipocytes constitute the predominant component of adipose tissue and are essential for executing its overall functions. The primary roles of adipocytes include metabolic regulation and distinct secretory activities.
Experimental evidence dating back to 1993 showed that metformin effectively attenuates chronic insulin exposure-induced reductions in GLUT4 expression on adipocyte membranes, indirectly supporting its potential in countering insulin-induced adipocyte senescence [108]. Similar results have been confirmed in human adipocytes [109]. The underlying mechanisms involve metformin’s modulation of insulin signaling pathways, AMPK activation, and enhanced GLUT4 translocation to the plasma membrane [110]. Metformin significantly reduces lipid accumulation in adipocytes by inhibiting insulin-induced lipogenesis and suppressing lipid droplet fusion [111]. It also attenuates adrenaline-or cAMP-stimulated lipolysis, reducing glycerol and free fatty acid release, thereby limiting adipocyte energy mobilization [112]. Even when hyperuricemia elevates free fatty acid levels and induces insulin resistance, metformin can mitigate these effects in white adipocytes [113]. Meanwhile, hyperinsulinemia and elevated blood glucose in T2DM contribute to adipocyte senescence. Classical senescence markers and additional indicators confirm the detrimental impact of senescence on adipocyte metabolic function and insulin sensitivity [114]. Under hyperinsulinemic conditions, metformin alleviates insulin-induced cellular senescence and reduces secretion of senescence-associated secretory phenotype factors and inflammatory cytokines [46]. These effects improve adipocyte function and may delay T2DM progression. Although direct evidence remains limited, metformin may indirectly stimulate differentiation of white adipocytes into beige adipocytes via AMPK pathway activation, enhancing energy expenditure [115]. Regarding exosome secretion, metformin attenuates exosome release from obese mouse white adipocytes through the AMPK pathway, mitigating fatty liver resulting from obesity-induced AMPK inhibition [116]. The molecular mechanisms underlying metformin’s direct regulation of adipocyte-derived exosomes remain unclear. It has yet to be determined whether metformin influences exosome biogenesis via classical pathways such as AMPK/mTOR or modifies exosomal cargo through epigenetic alterations [117]. Current research predominantly relies on cellular experiments or murine models, with scarce clinical data from human populations [118,119]. Moreover, heterogeneity among exosomes derived from different adipose depots has not been adequately explored [120]. The absence of standardized protocols for exosome isolation and characterization likely contributes to inconsistent reproducibility among studies.
By modulating metabolic activities, inflammatory responses, and differentiation processes in mature adipocytes, metformin exerts integrated effects such as reduced lipid storage, improved glucose metabolism, suppression of excessive lipolysis, and regulation of adipokine and exosome secretion. These actions underpin its therapeutic efficacy in obesity and diabetes. Additionally, metformin may influence systemic insulin sensitivity and cognitive function by regulating adipocyte-mediated metabolic pathways.
Adipose-derived stem cells
ASCs are a type of MSC with multipotent differentiation capabilities, providing significant potential in regenerative medicine, immunomodulation, and disease treatment. Owing to their accessibility, pluripotency, and robust paracrine activity, ASCs have become central tools in regenerative medicine, playing key roles in tissue repair, immune regulation, metabolic modulation, and potentially antifibrotic activities [121].
Metformin significantly inhibits the adipogenic differentiation of ASCs, reducing lipid droplet fusion and growth. This effect has been demonstrated in ASCs derived from both epididymal and inguinal fat depots. The underlying mechanism may involve the downregulation of adipogenesis-related proteins such as Cidec, Perilipin1, and Rab8a [122]. These observations align with earlier findings indicating that metformin suppresses differentiation and lipogenesis in 3T3–L1 cells [123]. Metformin administration significantly influences ASC morphology, proliferation rate, differentiation potential, and senescence, generally enhancing their proliferation and function. A murine study reported that prolonged metformin administration (8 weeks, 2.8 mg/day) increased ASC viability and proliferation while reducing their population doubling time [124]. These results align with findings from horse-derived ASCs, suggesting that metformin’s positive impact on viability, DNA synthesis, and metabolic efficiency correlates with increased mitochondrial membrane potential, reduced apoptosis, and elevated WNT3A/β-catenin expression [125]. Another study similarly demonstrated that metformin (5 mM) reduced the expression of lipogenic genes and lipid droplet accumulation, concurrently activating AMPK and thereby inhibiting human preadipocyte differentiation [32]. However, one specific study produced contrasting outcomes depending on metformin concentration: lower concentrations (1.25 to 2.5 mM) promoted adipogenesis potentially via an AMPK-independent pathway, whereas higher concentrations (5 to 10 mM) strongly inhibited adipogenesis through AMPK activation in 3T3–L1 cells [126]. Notably, metformin effectively prevents oxidative stress-induced senescence and dysfunction during ASC proliferation, thus restoring adipogenesis capacity [127]. In vitro studies have indicated that treatment with metformin significantly reduces oxidative stress in adipose tissue-derived precursor cells, especially those showing passage-related senescence from elderly donors, enhancing their adipogenic capacity and insulin sensitivity. In contrast, metformin exerts relatively modest effects in precursor cells from younger individuals. These anti-aging effects may partly involve AMPK phosphorylation and activation [127]. Furthermore, metformin increases the synthesis of membrane-derived vesicles, which contain numerous regenerative growth factors. Metformin-treated ASCs exhibit extensive networks of filopodia and lamellipodia [124]. These structures play a pivotal role in promoting both cell migration and extension, which are valuable characteristics in cells intended for regenerative medicine applications.
Metformin exerts multi-target regulatory effects on the metabolism, differentiation, immunomodulation, and regenerative capacity of ASCs, demonstrating therapeutic potential in obesity, diabetes complications, tissue engineering, and anti-aging therapies. Nevertheless, the precise mechanisms underlying these effects—particularly at physiologically relevant concentrations and the involvement of AMPK-dependent or independent pathways—remain unclear. Additionally, stem cell-based therapies have emerged as a promising area, yet detailed mechanistic studies and clinical validation in humans are necessary. Given metformin’s concentration-dependent influence on adipocyte differentiation and its differential anti-aging effects depending on cellular senescence status, carefully designed multicenter human studies with adequate sample sizes and ethical oversight are essential. Studies involving obese participants or individuals with diabetes must monitor both metabolic changes in transplanted ASCs and systemic metabolic improvements post-transplantation [128]. Long-term surveillance should include assessing abnormal tissue proliferation or tumor formation at transplantation sites, alongside evaluations of telomerase activity and senescence-associated genes such as p16 and p21 [129].
Metformin exerts profound and multidimensional effects on adipose tissue by modulating cellular metabolism, differentiation, inflammation, and regenerative processes. These actions occur through direct effects on mature adipocytes, ECM remodeling, and regulatory impacts on ASCs. Metformin improves insulin sensitivity, reduces excessive lipogenesis and lipolysis, alleviates inflammation, and delays cellular senescence primarily via AMPK activation. Specifically, metformin enhances metabolic function and limits hypertrophy in WAT, whereas it promotes thermogenesis and energy expenditure in BAT. The capacity of metformin to remodel adipose tissue at both cellular and molecular levels underlies its broad therapeutic potential in obesity, T2DM, and tissue engineering.
Despite promising findings, several challenges and questions persist. First, discrepancies between in vitro and in vivo studies— particularly regarding metformin concentrations—limit translational relevance. Many observed cellular effects occur at supraphysiological concentrations unattainable under standard clinical dosing, raising concerns about physiological applicability. Future studies should prioritize pharmacologically relevant concentrations and utilize advanced models such as organoids, three-dimensional cultures, or in vivo systems that better replicate systemic environments. Second, although AMPK is well-recognized as a critical target, increasing evidence indicates involvement of AMPK-independent mechanisms (e.g., lysosomal and redox regulation). Clarifying these additional pathways and their tissue-specific roles will enhance understanding of metformin’s mechanisms of action. Third, individual variability—including age, obesity status, genetic background, and adipose depot origin—may significantly influence metformin’s efficacy and mechanism of action. Implementing precision medicine approaches integrating genomics and metabolomics will help tailor metformin therapy across diverse populations. Finally, given the emerging significance of ASCs in regenerative medicine, understanding how metformin regulates their fate and function might pave the way for novel applications in tissue repair and anti-aging interventions. Nonetheless, long-term safety, dosage optimization, and potential off-target effects of metformin in stem-cell-based therapies require thorough evaluation.
In recent years, several novel antidiabetic agents, such as GLP-1 receptor agonists, have demonstrated both glucose-lowering and weight-reducing effects. Concurrently, GLP-1 receptor agonists have been observed to reduce pro-inflammatory cytokines (e.g., IL-1β and IL-6), thereby attenuating chronic inflammation. While metformin activates AMPK to enhance mitochondrial function, GLP-1 receptor agonists might further facilitate cellular repair via the PI3K/Akt signaling pathway. Combination therapies involving metformin and GLP-1 receptor agonists in diabetes models show superior metabolic improvements compared to monotherapy. These agents potentially exert complementary effects via distinct yet intersecting pathways like AMPK and PI3K/Akt, warranting further investigation into their molecular interactions.
In summary, although metformin remains foundational in managing metabolic diseases, expanding understanding of its role in adipose tissue biology and regenerative medicine opens new therapeutic avenues. Future research should aim to refine mechanistic insights, optimize dosing strategies, and explore novel therapeutic indications to fully harness the therapeutic potential of this century-old drug.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

ACKNOWLEDGMENTS

The authors thank https://www.biorender.com/ for providing the medical illustrations for this study.

Fig. 1.
The distribution and characteristics of different types of adipose tissue and the effects of metformin on them. ↑ represents promotion, ↓ represents inhibition. White adipose tissue is widely distributed subcutaneously throughout the body, especially in the abdomen, buttocks, thighs, and upper arms (subcutaneous fat), surrounding organs such as the liver and intestines (visceral fat), and in eye sockets, breasts, etc. (other special areas). Brown adipose tissue is mainly distributed in the supraclavicular area, deep neck, perivascular area (such as around the aorta and renal artery), paraspinal area, and perirenal area. UCP1, uncoupling protein 1.
enm-2025-2371f1.jpg
Fig. 2.
Effects of metformin on various cell types in adipose tissue, including extracellular matrix (ECM), mature adipocytes, and adipose-derived stem cells (ASCs). ↑ represents promotion, ↓ represents inhibition. MMP, matrix metalloproteinase; MSC, mesenchymal stem cell; GLUT4, glucose transporter 4; ROS, reactive oxygen species.
enm-2025-2371f2.jpg
enm-2025-2371f3.jpg
  • 1. Papachristodoulou A, Heidegger I, Virk RK, Di Bernardo M, Kim JY, Laplaca C, et al. Metformin overcomes the consequences of NKX3.1 loss to suppress prostate cancer progression. Eur Urol 2024;85:361–72.ArticlePubMedPMC
  • 2. Malaekeh-Nikouei A, Shokri-Naei S, Karbasforoushan S, Bahari H, Baradaran Rahimi V, Heidari R, et al. Metformin beyond an anti-diabetic agent: a comprehensive and mechanistic review on its effects against natural and chemical toxins. Biomed Pharmacother 2023;165:115263.ArticlePubMed
  • 3. Sakers A, De Siqueira MK, Seale P, Villanueva CJ. Adipose-tissue plasticity in health and disease. Cell 2022;185:419–46.ArticlePubMedPMC
  • 4. Bailey CJ, Day C. Traditional plant medicines as treatments for diabetes. Diabetes Care 1989;12:553–64.ArticlePubMedPDF
  • 5. Bailey CJ, Day C. Metformin: its botanical background. Pract Diabetes Int 2004;21:115–7.Article
  • 6. Werner EA, Bell J. CCXIV: the preparation of methylguanidine, and of ββ-dimethylguanidine by the interaction of dicyanodiamide, and methylammonium and dimethylammonium chlorides respectively. J Chem Soc Trans 1922;121:1790–4.Article
  • 7. Bailey CJ. Metformin: historical overview. Diabetologia 2017;60:1566–76.ArticlePubMedPDF
  • 8. Garcia EY. Flumamine, a new synthetic analgesic and antiflu drug. J Philipp Med Assoc 1950;26:287–93.PubMed
  • 9. Curd FH, Davey DG, Rose FL. Studies on synthetic antimalarial drugs: some biguanide derivatives as new types of antimalarial substances with both therapeutic and causal prophylactic activity. Ann Trop Med Parasitol 1945;39:208–16.PubMed
  • 10. Sterne J. Treatment of diabetes mellitus with N,N-dimethylguanylguanidine (LA. 6023, glucophage). Therapie 1959;14:625–30.PubMed
  • 11. Garber AJ, Larsen J, Schneider SH, Piper BA, Henry D; Glyburide/Metformin Initial Therapy Study Group. Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabetes Obes Metab 2002;4:201–8.ArticlePubMed
  • 12. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995;333:541–9.ArticlePubMed
  • 13. Schernthaner G, Schernthaner GH. The right place for metformin today. Diabetes Res Clin Pract 2020;159:107946.ArticlePubMed
  • 14. Esposito K, Chiodini P, Bellastella G, Maiorino MI, Giugliano D. Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients. Diabetes Obes Metab 2012;14:228–33.ArticlePubMed
  • 15. Sherifali D, Nerenberg K, Pullenayegum E, Cheng JE, Gerstein HC. The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care 2010;33:1859–64.PubMedPMC
  • 16. Villikudathil AT, Mc Guigan DH, English A. Exploring metformin monotherapy response in type-2 diabetes: computational insights through clinical, genomic, and proteomic markers using machine learning algorithms. Comput Biol Med 2024;171:108106.ArticlePubMed
  • 17. Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 2012;344:e1369.ArticlePubMed
  • 18. GRADE Study Research Group, Nathan DM, Lachin JM, Balasubramanyam A, Burch HB, Buse JB, et al. Glycemia reduction in type 2 diabetes: glycemic outcomes. N Engl J Med 2022;387:1063–74.ArticlePubMedPMC
  • 19. Echouffo-Tcheugui JB, Perreault L, Ji L, Dagogo-Jack S. Diagnosis and management of prediabetes: a review. JAMA 2023;329:1206–16.ArticlePubMed
  • 20. Zhang L, Zhang Y, Shen S, Wang X, Dong L, Li Q, et al. Safety and effectiveness of metformin plus lifestyle intervention compared with lifestyle intervention alone in preventing progression to diabetes in a Chinese population with impaired glucose regulation: a multicentre, open-label, randomised controlled trial. Lancet Diabetes Endocrinol 2023;11:567–77.PubMed
  • 21. Schernthaner G, Brand K, Bailey CJ. Metformin and the heart: update on mechanisms of cardiovascular protection with special reference to comorbid type 2 diabetes and heart failure. Metabolism 2022;130:155160.ArticlePubMed
  • 22. Ding Y, Zhou Y, Ling P, Feng X, Luo S, Zheng X, et al. Metformin in cardiovascular diabetology: a focused review of its impact on endothelial function. Theranostics 2021;11:9376–96.ArticlePubMedPMC
  • 23. Zhang Y, Li D, Zhu Z, Chen S, Lu M, Cao P, et al. Evaluating the impact of metformin targets on the risk of osteoarthritis: a mendelian randomization study. Osteoarthritis Cartilage 2022;30:1506–14.ArticlePubMed
  • 24. Joham AE, Norman RJ, Stener-Victorin E, Legro RS, Franks S, Moran LJ, et al. Polycystic ovary syndrome. Lancet Diabetes Endocrinol 2022;10:668–80.ArticlePubMed
  • 25. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes: 2023. Diabetes Care 2023;46(Suppl 1):S140–57.PubMedPMC
  • 26. Flory J, Lipska K. Metformin in 2019. JAMA 2019;321:1926–7.ArticlePubMedPMC
  • 27. Aroda VR, Edelstein SL, Goldberg RB, Knowler WC, Marcovina SM, Orchard TJ, et al. Long-term metformin use and vitamin B12 deficiency in the diabetes prevention program outcomes study. J Clin Endocrinol Metab 2016;101:1754–61.ArticlePubMedPMCPDF
  • 28. Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin: from mechanisms of action to therapies. Cell Metab 2014;20:953–66.ArticlePubMed
  • 29. Dawed AY, Zhou K, van Leeuwen N, Mahajan A, Robertson N, Koivula R, et al. Variation in the plasma membrane monoamine transporter (PMAT) (encoded by SLC29A4) and organic cation transporter 1 (OCT1) (encoded by SLC22A1) and gastrointestinal intolerance to metformin in type 2 diabetes: an IMI DIRECT Study. Diabetes Care 2019;42:1027–33.PubMed
  • 30. Nies AT, Koepsell H, Winter S, Burk O, Klein K, Kerb R, et al. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology 2009;50:1227–40.ArticlePubMed
  • 31. Chen L, Shu Y, Liang X, Chen EC, Yee SW, Zur AA, et al. OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin. Proc Natl Acad Sci U S A 2014;111:9983–8.ArticlePubMedPMC
  • 32. Moreno-Navarrete JM, Ortega FJ, Rodriguez-Hermosa JI, Sabater M, Pardo G, Ricart W, et al. OCT1 expression in adipocytes could contribute to increased metformin action in obese subjects. Diabetes 2011;60:168–76.ArticlePubMedPMCPDF
  • 33. Suo Y, Wright NJ, Guterres H, Fedor JG, Butay KJ, Borgnia MJ, et al. Molecular basis of polyspecific drug and xenobiotic recognition by OCT1 and OCT2. Nat Struct Mol Biol 2023;30:1001–11.ArticlePubMedPMCPDF
  • 34. Tsuda M, Terada T, Ueba M, Sato T, Masuda S, Katsura T, et al. Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. J Pharmacol Exp Ther 2009;329:185–91.ArticlePubMed
  • 35. Kusuhara H, Ito S, Kumagai Y, Jiang M, Shiroshita T, Moriyama Y, et al. Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects. Clin Pharmacol Ther 2011;89:837–44.ArticlePubMed
  • 36. Masuda S, Terada T, Yonezawa A, Tanihara Y, Kishimoto K, Katsura T, et al. Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol 2006;17:2127–35.ArticlePubMed
  • 37. Shao R, Li X, Feng Y, Lin JF, Billig H. Direct effects of metformin in the endometrium: a hypothetical mechanism for the treatment of women with PCOS and endometrial carcinoma. J Exp Clin Cancer Res 2014;33:41.ArticlePubMedPMCPDF
  • 38. Bresciani N, Demagny H, Lemos V, Pontanari F, Li X, Sun Y, et al. The Slc25a47 locus is a novel determinant of hepatic mitochondrial function implicated in liver fibrosis. J Hepatol 2022;77:1071–82.ArticlePubMed
  • 39. Cheng L, Deepak RN, Wang G, Meng Z, Tao L, Xie M, et al. Hepatic mitochondrial NAD + transporter SLC25A47 activates AMPKα mediating lipid metabolism and tumorigenesis. Hepatology 2023;78:1828–42.ArticlePubMedPMC
  • 40. Kaplanian M, Philippe C, Eid SA, Hackl MT, Metz M, Beghini M, et al. Deciphering metformin action in obese mice: a critical re-evaluation of established protocols. Metabolism 2022;128:154956.ArticlePubMed
  • 41. LaMoia TE, Shulman GI. Cellular and molecular mechanisms of metformin action. Endocr Rev 2021;42:77–96.ArticlePubMedPMCPDF
  • 42. He L, Wondisford FE. Metformin action: concentrations matter. Cell Metab 2015;21:159–62.ArticlePubMed
  • 43. Sakamoto K, Jessen N. PEN2: metformin’s new partner at lysosome. Cell Res 2022;32:507–8.ArticlePubMedPMCPDF
  • 44. Foretz M, Guigas B, Viollet B. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nat Rev Endocrinol 2019;15:569–89.ArticlePubMedPDF
  • 45. Foretz M, Guigas B, Viollet B. Metformin: update on mechanisms of action and repurposing potential. Nat Rev Endocrinol 2023;19:460–76.ArticlePubMedPMCPDF
  • 46. Li Q, Hagberg CE, Silva Cascales H, Lang S, Hyvonen MT, Salehzadeh F, et al. Obesity and hyperinsulinemia drive adipocytes to activate a cell cycle program and senesce. Nat Med 2021;27:1941–53.ArticlePubMedPDF
  • 47. Ma T, Tian X, Zhang B, Li M, Wang Y, Yang C, et al. Low-dose metformin targets the lysosomal AMPK pathway through PEN2. Nature 2022;603:159–65.PubMedPMC
  • 48. Sundelin E, Jensen JB, Jakobsen S, Gormsen LC, Jessen N. Metformin biodistribution: a key to mechanisms of action? J Clin Endocrinol Metab 2020;105:3374–83.ArticlePDF
  • 49. Gormsen LC, Sundelin EI, Jensen JB, Vendelbo MH, Jakobsen S, Munk OL, et al. In vivo imaging of human 11C-metformin in peripheral organs: dosimetry, biodistribution, and kinetic analyses. J Nucl Med 2016;57:1920–6.ArticlePubMed
  • 50. Sundelin EI, Gormsen LC, Heeboll S, Vendelbo MH, Jakobsen S, Munk OL, et al. Hepatic exposure of metformin in patients with non-alcoholic fatty liver disease. Br J Clin Pharmacol 2019;85:1761–70.ArticlePubMedPMCPDF
  • 51. Vercellino I, Sazanov LA. The assembly, regulation and function of the mitochondrial respiratory chain. Nat Rev Mol Cell Biol 2022;23:141–61.ArticlePubMedPDF
  • 52. Oakhill JS, Steel R, Chen ZP, Scott JW, Ling N, Tam S, et al. AMPK is a direct adenylate charge-regulated protein kinase. Science 2011;332:1433–5.ArticlePubMed
  • 53. Gan B, Hu J, Jiang S, Liu Y, Sahin E, Zhuang L, et al. Lkb1 regulates quiescence and metabolic homeostasis of haematopoietic stem cells. Nature 2010;468:701–4.ArticlePubMedPMCPDF
  • 54. Pencik J, Philippe C, Schlederer M, Atas E, Pecoraro M, Grund-Groschke S, et al. STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway. Mol Cancer 2023;22:133.ArticlePubMedPMCPDF
  • 55. Molaei A, Molaei E, Sadeghnia H, Hayes AW, Karimi G. LKB1: an emerging therapeutic target for cardiovascular diseases. Life Sci 2022;306:120844.ArticlePubMed
  • 56. Borzi C, Ganzinelli M, Caiola E, Colombo M, Centonze G, Boeri M, et al. LKB1 down-modulation by miR-17 identifies patients with NSCLC having worse prognosis eligible for energy-stress-based treatments. J Thorac Oncol 2021;16:1298–311.ArticlePubMed
  • 57. Zhang CS, Hawley SA, Zong Y, Li M, Wang Z, Gray A, et al. Fructose-1,6-bisphosphate and aldolase mediate glucose sensing by AMPK. Nature 2017;548:112–6.ArticlePubMedPMCPDF
  • 58. Zhang CS, Li M, Wang Y, Li X, Zong Y, Long S, et al. The aldolase inhibitor aldometanib mimics glucose starvation to activate lysosomal AMPK. Nat Metab 2022;4:1369–401.ArticlePubMedPMCPDF
  • 59. Miller RA, Chu Q, Xie J, Foretz M, Viollet B, Birnbaum MJ. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 2013;494:256–60.ArticlePubMedPMCPDF
  • 60. Shi P, Liu W, Wang H, Li F, Zhang H, et al. Metformin suppresses triple-negative breast cancer stem cells by targeting KLF5 for degradation. Cell Discov 2017;3:17010.ArticlePubMedPMCPDF
  • 61. Stein BD, Calzolari D, Hellberg K, Hu YS, He L, Hung CM, et al. Quantitative in vivo proteomics of metformin response in liver reveals AMPK-dependent and -independent signaling networks. Cell Rep 2019;29:3331–48.ArticlePubMedPMC
  • 62. Madiraju AK, Erion DM, Rahimi Y, Zhang XM, Braddock DT, Albright RA, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 2014;510:542–6.ArticlePubMedPMCPDF
  • 63. Alshawi A, Agius L. Low metformin causes a more oxidized mitochondrial NADH/NAD redox state in hepatocytes and inhibits gluconeogenesis by a redox-independent mechanism. J Biol Chem 2019;294:2839–53.ArticlePubMedPMC
  • 64. Lawrence RE, Zoncu R. The lysosome as a cellular centre for signalling, metabolism and quality control. Nat Cell Biol 2019;21:133–42.ArticlePubMedPDF
  • 65. Zhang CS, Li M, Ma T, Zong Y, Cui J, Feng JW, et al. Metformin activates AMPK through the lysosomal pathway. Cell Metab 2016;24:521–2.ArticlePubMed
  • 66. Wang L, Wu D, Robinson CV, Wu H, Fu TM. Structures of a complete human V-ATPase reveal mechanisms of its assembly. Mol Cell 2020;80:501–11.ArticlePubMedPMC
  • 67. Steinberg GR, Carling D. AMP-activated protein kinase: the current landscape for drug development. Nat Rev Drug Discov 2019;18:527–51.ArticlePubMedPDF
  • 68. Hao JW, Wang J, Guo H, Zhao YY, Sun HH, Li YF, et al. CD36 facilitates fatty acid uptake by dynamic palmitoylation-regulated endocytosis. Nat Commun 2020;11:4765.ArticlePubMedPMCPDF
  • 69. Leto D, Saltiel AR. Regulation of glucose transport by insulin: traffic control of GLUT4. Nat Rev Mol Cell Biol 2012;13:383–96.ArticlePubMedPDF
  • 70. Wallace M, Metallo CM. Tracing insights into de novo lipogenesis in liver and adipose tissues. Semin Cell Dev Biol 2020;108:65–71.ArticlePubMed
  • 71. Morigny P, Boucher J, Arner P, Langin D. Lipid and glucose metabolism in white adipocytes: pathways, dysfunction and therapeutics. Nat Rev Endocrinol 2021;17:276–95.ArticlePubMedPDF
  • 72. Cypess AM. Reassessing human adipose tissue. N Engl J Med 2022;386:768–79.ArticlePubMed
  • 73. Sanchez-Gurmaches J, Hung CM, Guertin DA. Emerging complexities in adipocyte origins and identity. Trends Cell Biol 2016;26:313–26.ArticlePubMedPMC
  • 74. Lidell ME, Betz MJ, Dahlqvist Leinhard O, Heglind M, Elander L, Slawik M, et al. Evidence for two types of brown adipose tissue in humans. Nat Med 2013;19:631–4.ArticlePubMedPDF
  • 75. Scheele C, Wolfrum C. Brown adipose crosstalk in tissue plasticity and human metabolism. Endocr Rev 2020;41:53–65.ArticlePubMedPMCPDF
  • 76. Jung SM, Sanchez-Gurmaches J, Guertin DA. Brown adipose tissue development and metabolism. Handb Exp Pharmacol 2019;251:3–36.ArticlePubMedPMC
  • 77. Wang W, Seale P. Control of brown and beige fat development. Nat Rev Mol Cell Biol 2016;17:691–702.ArticlePubMedPMCPDF
  • 78. Cohen P, Levy JD, Zhang Y, Frontini A, Kolodin DP, Svensson KJ, et al. Ablation of PRDM16 and beige adipose causes metabolic dysfunction and a subcutaneous to visceral fat switch. Cell 2014;156:304–16.ArticlePubMedPMC
  • 79. Karise I, Bargut TC, Del Sol M, Aguila MB, Mandarim-de-Lacerda CA. Metformin enhances mitochondrial biogenesis and thermogenesis in brown adipocytes of mice. Biomed Pharmacother 2019;111:1156–65.ArticlePubMed
  • 80. Liang G, Fang J, Zhang P, Ding S, Zhao Y, Feng Y. Metformin plus L-carnitine enhances brown/beige adipose tissue activity via Nrf2/HO-1 signaling to reduce lipid accumulation and inflammation in murine obesity. Open Med (Wars) 2024;19:20240900.ArticlePubMedPMC
  • 81. Kim EK, Lee SH, Jhun JY, Byun JK, Jeong JH, Lee SY, et al. Metformin prevents fatty liver and improves balance of white/brown adipose in an obesity mouse model by inducing FGF21. Mediators Inflamm 2016;2016:5813030.ArticlePubMedPMCPDF
  • 82. Xiang X, Feng Y, Li H, Li W, Li J, Xia Z, et al. Metformin delays the decline in thermogenic function of brown adipose tissue in a mouse model of Hutchinson-Gilford progeria syndrome. Exp Gerontol 2025;201:112702.ArticlePubMed
  • 83. Geerling JJ, Boon MR, van der Zon GC, van den Berg SA, van den Hoek AM, Lombes M, et al. Metformin lowers plasma triglycerides by promoting VLDL-triglyceride clearance by brown adipose tissue in mice. Diabetes 2014;63:880–91.ArticlePubMedPDF
  • 84. Pescador N, Francisco V, Vazquez P, Esquinas EM, Gonzalez-Paramos C, Valdecantos MP, et al. Metformin reduces macrophage HIF1α-dependent proinflammatory signaling to restore brown adipocyte function in vitro. Redox Biol 2021;48:102171.ArticlePubMedPMC
  • 85. Ziqubu K, Mazibuko-Mbeje SE, Mthembu SX, Mabhida SE, Jack BU, Nyambuya TM, et al. Anti-obesity effects of metformin: a scoping review evaluating the feasibility of brown adipose tissue as a therapeutic target. Int J Mol Sci 2023;24:2227.ArticlePubMedPMC
  • 86. Grabner GF, Xie H, Schweiger M, Zechner R. Lipolysis: cellular mechanisms for lipid mobilization from fat stores. Nat Metab 2021;3:1445–65.ArticlePubMedPDF
  • 87. Guo C, Liu J, Li H. Metformin ameliorates olanzapine-induced insulin resistance via suppressing macrophage infiltration and inflammatory responses in rats. Biomed Pharmacother 2021;133:110912.ArticlePubMed
  • 88. Thierry S, Peterson CJ, Pfammatter S, Tardio PA, Meier C, Delko T, et al. Short-term metformin protects against glucocorticoid-induced toxicity in healthy individuals: a randomized, double-blind, placebo-controlled trial. Diabetes Care 2025;48:719–27.PubMedPMC
  • 89. Dludla PV, Nkambule BB, Mazibuko-Mbeje SE, Nyambuya TM, Mxinwa V, Mokgalaboni K, et al. Adipokines as a therapeutic target by metformin to improve metabolic function: a systematic review of randomized controlled trials. Pharmacol Res 2021;163:105219.ArticlePubMed
  • 90. Zhao D, Sohouli MH, Rohani P, Fotros D, Velu P, Ziamanesh F, et al. The effect of metformin on adipokines levels: a systematic review and meta-analysis of randomized-controlled trials. Diabetes Res Clin Pract 2024;207:111076.ArticlePubMed
  • 91. Yao L, Wang L, Zhang R, Soukas AA, Wu L. The direct targets of metformin in diabetes and beyond. Trends Endocrinol Metab 2025;36:364–72.ArticlePubMed
  • 92. Tandon P, Wafer R, Minchin JE. Adipose morphology and metabolic disease. J Exp Biol 2018;221(Pt Suppl 1):jeb164970.ArticlePubMedPDF
  • 93. Pellegrinelli V, Carobbio S, Vidal-Puig A. Adipose tissue plasticity: how fat depots respond differently to pathophysiological cues. Diabetologia 2016;59:1075–88.ArticlePubMedPMCPDF
  • 94. Hoffstedt J, Arner E, Wahrenberg H, Andersson DP, Qvisth V, Lofgren P, et al. Regional impact of adipose tissue morphology on the metabolic profile in morbid obesity. Diabetologia 2010;53:2496–503.ArticlePubMedPDF
  • 95. Agarwal SM, Panda R, Costa-Dookhan KA, MacKenzie NE, Treen QC, Caravaggio F, et al. Metformin for early comorbid glucose dysregulation and schizophrenia spectrum disorders: a pilot double-blind randomized clinical trial. Transl Psychiatry 2021;11:219.ArticlePubMedPMCPDF
  • 96. Choi JY, Jang TW, Song PH, Choi SH, Ku SK, Song CH. Combination effects of metformin and a mixture of lemon balm and dandelion on high-fat diet-induced metabolic alterations in mice. Antioxidants (Basel) 2022;11:580.ArticlePubMedPMC
  • 97. He L. Metformin and systemic metabolism. Trends Pharmacol Sci 2020;41:868–81.ArticlePubMedPMC
  • 98. Crewe C, An YA, Scherer PE. The ominous triad of adipose tissue dysfunction: inflammation, fibrosis, and impaired angiogenesis. J Clin Invest 2017;127:74–82.ArticlePubMedPMC
  • 99. Halberg N, Khan T, Trujillo ME, Wernstedt-Asterholm I, Attie AD, Sherwani S, et al. Hypoxia-inducible factor 1alpha induces fibrosis and insulin resistance in white adipose tissue. Mol Cell Biol 2009;29:4467–83.ArticlePubMedPMCPDF
  • 100. Lin D, Chun TH, Kang L. Adipose extracellular matrix remodelling in obesity and insulin resistance. Biochem Pharmacol 2016;119:8–16.ArticlePubMedPMC
  • 101. Luo T, Nocon A, Fry J, Sherban A, Rui X, Jiang B, et al. AMPK activation by metformin suppresses abnormal extracellular matrix remodeling in adipose tissue and ameliorates insulin resistance in obesity. Diabetes 2016;65:2295–310.ArticlePubMedPMCPDF
  • 102. Septembre-Malaterre A, Boina C, Douanier A, Gasque P. Deciphering the antifibrotic property of metformin. Cells 2022;11:4090.ArticlePubMedPMC
  • 103. Biondo LA, Batatinha HA, Souza CO, Teixeira AA, Silveira LS, Alonso-Vale MI, et al. Metformin mitigates fibrosis and glucose intolerance induced by doxorubicin in subcutaneous adipose tissue. Front Pharmacol 2018;9:452.ArticlePubMedPMC
  • 104. Chen H, Liu P, Pan X, Huang M, Li T, Guo Y, et al. Downregulation of collagen IV deposition and ITGB1-FAK signaling pathway to inhibit adipogenesis: a novel mechanism of swertiamarin in treating type 2 diabetes mellitus. Int J Biol Macromol 2025;299:140048.ArticlePubMed
  • 105. Marcelin G, Da Cunha C, Gamblin C, Suffee N, Rouault C, Leclerc A, et al. Autophagy inhibition blunts PDGFRA adipose progenitors’ cell-autonomous fibrogenic response to high-fat diet. Autophagy 2020;16:2156–66.ArticlePubMedPMC
  • 106. Shi L, Jiang Z, Li J, Lin H, Xu B, Liao X, et al. Metformin improves burn wound healing by modulating microenvironmental fibroblasts and macrophages. Cells 2022;11:4094.ArticlePubMedPMC
  • 107. Duan S, Sun F, Qiao P, Zhu Z, Geng M, Gong X, et al. Detachable dual-targeting nanoparticles for improving the antitumor effect by extracellular matrix depletion. ACS Biomater Sci Eng 2023;9:1437–49.ArticlePubMedPDF
  • 108. Kozka IJ, Holman GD. Metformin blocks downregulation of cell surface GLUT4 caused by chronic insulin treatment of rat adipocytes. Diabetes 1993;42:1159–65.ArticlePubMed
  • 109. Grisouard J, Timper K, Radimerski TM, Frey DM, Peterli R, Kola B, et al. Mechanisms of metformin action on glucose transport and metabolism in human adipocytes. Biochem Pharmacol 2010;80:1736–45.ArticlePubMed
  • 110. Herman R, Kravos NA, Jensterle M, Janez A, Dolzan V. Metformin and insulin resistance: a review of the underlying mechanisms behind changes in GLUT4-mediated glucose transport. Int J Mol Sci 2022;23:1264.ArticlePubMedPMC
  • 111. Zhao Z, Wang C, Jia J, Wang Z, Li L, Deng X, et al. Regulatory network of metformin on adipogenesis determined by combining high-throughput sequencing and GEO database. Adipocyte 2022;11:56–68.ArticlePubMedPMC
  • 112. Szkudelski T, Konieczna K, Szkudelska K. Regulatory effects of metformin, an antidiabetic biguanide drug, on the metabolism of primary rat adipocytes. Molecules 2022;27:5250.ArticlePubMedPMC
  • 113. Su M, Sun L, Li W, Liu H, Liu Y, Wei Y, et al. Metformin alleviates hyperuricaemia-induced serum FFA elevation and insulin resistance by inhibiting adipocyte hypertrophy and reversing suppressed white adipose tissue beiging. Clin Sci (Lond) 2020;134:1537–53.ArticlePubMedPDF
  • 114. Gustafson B, Nerstedt A, Spinelli R, Beguinot F, Smith U. Type 2 diabetes, independent of obesity and age, is characterized by senescent and dysfunctional mature human adipose cells. Diabetes 2022;71:2372–83.ArticlePubMedPDF
  • 115. Zhang P, He Y, Wu S, Li X, Lin X, Gan M, et al. Factors associated with white fat browning: new regulators of lipid metabolism. Int J Mol Sci 2022;23:7641.ArticlePubMedPMC
  • 116. Yan C, Tian X, Li J, Liu D, Ye D, Xie Z, et al. A high-fat diet attenuates AMPK α1 in adipocytes to induce exosome shedding and nonalcoholic fatty liver development in vivo. Diabetes 2021;70:577–88.ArticlePubMedPMCPDF
  • 117. Abbasi R, Nejati V, Rezaie J. Exosomes biogenesis was increased in metformin-treated human ovary cancer cells: possibly to mediate resistance. Cancer Cell Int 2024;24:137.ArticlePubMedPMCPDF
  • 118. Son T, Jeong I, Park J, Jun W, Kim A, Kim OK. Adipose tissue-derived exosomes contribute to obesity-associated liver diseases in long-term high-fat diet-fed mice, but not in short-term. Front Nutr 2023;10:1162992.ArticlePubMedPMC
  • 119. Kim Y, Son T, Park J, Jun W, Kim OK. Role of exosomes derived from adipose tissue under obese conditions in skeletal muscle and liver cells: commonalities and differences. Mol Nutr Food Res 2022;66:e2200358.ArticlePubMedPDF
  • 120. Chen M, Zhang F, Chen B, Lau C, Xu K, Tong T, et al. Omics approach to reveal the effects of obesity on the protein profiles of the exosomes derived from different adipose depots. Cell Mol Life Sci 2022;79:570.ArticlePubMedPMCPDF
  • 121. Soltani A, Moradi M, Nejad AR, Moradi S, Javandoost E, Nazari H, et al. Adipose-derived stem cells: potentials, availability and market size in regenerative medicine. Curr Stem Cell Res Ther 2023;18:347–79.ArticlePubMedPDF
  • 122. Yang L, Jia X, Fang D, Cheng Y, Zhai Z, Deng W, et al. Metformin inhibits lipid droplets fusion and growth via reduction in Cidec and its regulatory factors in rat adipose-derived stem cells. Int J Mol Sci 2022;23:5986.ArticlePubMedPMC
  • 123. Alexandre KB, Smit AM, Gray IP, Crowther NJ. Metformin inhibits intracellular lipid accumulation in the murine preadipocyte cell line, 3T3-L1. Diabetes Obes Metab 2008;10:688–90.ArticlePubMed
  • 124. Marycz K, Tomaszewski KA, Kornicka K, Henry BM, Wronski S, Tarasiuk J, et al. Metformin decreases reactive oxygen species, enhances osteogenic properties of adipose-derived multipotent mesenchymal stem cells in vitro, and increases bone density in vivo. Oxid Med Cell Longev 2016;2016:9785890.ArticlePubMedPMCPDF
  • 125. Smieszek A, Kornicka K, Szlapka-Kosarzewska J, Androvic P, Valihrach L, Langerova L, et al. Metformin increases proliferative activity and viability of multipotent stromal stem cells isolated from adipose tissue derived from horses with equine metabolic syndrome. Cells 2019;8:80.ArticlePubMedPMC
  • 126. Chen D, Wang Y, Wu K, Wang X. Dual effects of metformin on adipogenic differentiation of 3T3-L1 preadipocyte in AMPK-dependent and independent manners. Int J Mol Sci 2018;19:1547.ArticlePubMedPMC
  • 127. Le Pelletier L, Mantecon M, Gorwood J, Auclair M, Foresti R, Motterlini R, et al. Metformin alleviates stress-induced cellular senescence of aging human adipose stromal cells and the ensuing adipocyte dysfunction. Elife 2021;10:e62635.PubMedPMC
  • 128. Duan W, Zou H, Zang N, Ma D, Yang B, Zhu L. Metformin increases bone marrow adipose tissue by promoting mesenchymal stromal cells apoptosis. Aging (Albany NY) 2023;15:542–52.ArticlePubMedPMC
  • 129. Nystrom M, Lauvrud AT, Perez-Diaz S, Kingham PJ, Wiberg R. Interaction of adipose-derived stem cells with active and dormant breast cancer cells. J Plast Reconstr Aesthet Surg 2023;83:69–76.ArticlePubMed

Figure & Data

References

    Citations

    Citations to this article as recorded by  
    • Mitochondrial dynamics in cisplatin resistance: molecular mechanisms and therapeutic targeting
      Wei Huang, Wei Sun, Zhiyuan Yang, Yiwen Li, Ziliang Wang
      Frontiers in Oncology.2026;[Epub]     CrossRef
    • The role of short-term metformin in regulating zinc and adipose tissue-derived biomarkers in children with obesity and insulin resistance
      Humeyra Acikan, Ayse Isik, Emre Sarikaya, Sabahattin Muhtaroglu, Nihal Hatipoglu
      BMC Endocrine Disorders.2026;[Epub]     CrossRef
    • Metformin in skin diseases: the role of gut microbiota and immune response
      Aneta Kiecka, Barbara Macura, Marian Szczepanik
      Pharmacological Reports.2026; 78(2): 391.     CrossRef
    • The Multifaceted Role of Metformin in Type 2 Diabetes: Mechanisms, Clinical Evidence, and Future Directions
      Pratik Rajale, Nilesh Meshram, Kuldeep Vinchurkar, Laxmikant Borse
      SN Comprehensive Clinical Medicine.2026;[Epub]     CrossRef
    • The Molecular Mechanisms Underlying Dercum’s Disease: Exploring the Intersection of Obesity, Pain, and Inflammation
      Claudia Reytor-González, Emilia Jiménez-Flores, Melannie Toral-Noristz, Martín Campuzano-Donoso, Náthaly Mercedes Román-Galeano, Daniel Simancas-Racines
      International Journal of Molecular Sciences.2025; 26(22): 11130.     CrossRef
    • Multiple Therapeutic Applications of Metformin Moving Beyond Its Anti-Diabetic Role:
      Asif Jan, Aftab Ullah, Syed Shaukat Ali, Rani Akbar, Bushra Waheed
      Journal of the ASEAN Federation of Endocrine Societies.2025; 40(2): 148.     CrossRef

    • PubReader PubReader
    • ePub LinkePub Link
    • Cite
      Cite
      export Copy Download
      Close
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.
      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      Metformin and Adipose Tissue: A Multifaceted Regulator in Metabolism, Inflammation, and Regeneration
      Endocrinol Metab. 2025;40(4):523-538.   Published online August 8, 2025
      DOI: https://doi.org/10.3803/EnM.2025.2371
      Close
    • XML DownloadXML Download
    Figure
    • 0
    • 1
    • 2
    Metformin and Adipose Tissue: A Multifaceted Regulator in Metabolism, Inflammation, and Regeneration
    Image Image Image
    Fig. 1. The distribution and characteristics of different types of adipose tissue and the effects of metformin on them. ↑ represents promotion, ↓ represents inhibition. White adipose tissue is widely distributed subcutaneously throughout the body, especially in the abdomen, buttocks, thighs, and upper arms (subcutaneous fat), surrounding organs such as the liver and intestines (visceral fat), and in eye sockets, breasts, etc. (other special areas). Brown adipose tissue is mainly distributed in the supraclavicular area, deep neck, perivascular area (such as around the aorta and renal artery), paraspinal area, and perirenal area. UCP1, uncoupling protein 1.
    Fig. 2. Effects of metformin on various cell types in adipose tissue, including extracellular matrix (ECM), mature adipocytes, and adipose-derived stem cells (ASCs). ↑ represents promotion, ↓ represents inhibition. MMP, matrix metalloproteinase; MSC, mesenchymal stem cell; GLUT4, glucose transporter 4; ROS, reactive oxygen species.
    Graphical abstract

    Fig. 1.

    Fig. 2.

    Graphical abstract

    Metformin and Adipose Tissue: A Multifaceted Regulator in Metabolism, Inflammation, and Regeneration
    Endocrinol Metab : Endocrinology and Metabolism
    © Korean Endocrine Society.
    TOP